You are here

drug pricing

Greenwood : In Drug Pricing Debate, Politicians and Patients Are Not Talking About Same Price

BIOTechNow

Wed, 06/5/19 - 12:09 am

Patients, payers await pricing plans for bluebird's first approved gene therapy

BioCentury

Tue, 06/4/19 - 11:04 am

beta thalassemia

Is $2.1 million too much for a drug? For affected parents, there is no debate

Stat

Mon, 06/3/19 - 11:28 am

Why Concerns About a “Break Down” in Drug Pricing Are Misplaced

BIOTechNow

Sat, 06/1/19 - 12:40 pm

Is CEO pay linked to drug prices? Curious investors failed their campaign to find out

Fierce Pharma

Thu, 05/30/19 - 05:35 pm

On the pulse of ASCO: pricing and clinical trial access

Pharmaforum

Thu, 05/30/19 - 09:37 am

clinical trial access

clinical trials

Maryland creates drug affordability review board

BioCentury

Tue, 05/28/19 - 11:16 pm

drug affordability review board

Trump Ready To Force Transparency In Healthcare Pricing With An Executive Order

Forbes

Mon, 05/27/19 - 11:50 pm

Novartis gene therapy approved, but will come at cost of more than $2 million

Biopharma Dive

Fri, 05/24/19 - 11:45 pm

A new Senate health package includes surprisingly aggressive drug pricing reforms

Stat

Thu, 05/23/19 - 10:48 pm

Colorado becomes first state to cap out-of-pocket insulin costs

The Hill

Thu, 05/23/19 - 10:41 pm

Eli Lilly’s Generic Insulin Hits Market at Half the Price of Branded Counterpart

BioSpace

Thu, 05/23/19 - 12:28 pm

Novartis CEO plans gene therapy price 'far lower' than $4 million to $5 million range

Yahoo/Reuters

Thu, 05/23/19 - 09:48 am

Decree of transparency at issue in House hearing on drug pricing bills

BioCentury

Tue, 05/21/19 - 11:05 pm

ICER seeks to make drug price research more accessible

Biopharma Dive

Mon, 05/20/19 - 11:10 pm

AbbVie's discounting Humira to aid Skyrizi's launch—and a price war could follow: analyst

Fierce Pharma

Mon, 05/20/19 - 11:07 pm

Gilead defends Truvada pricing during House hearing

BioCentury

Thu, 05/16/19 - 11:26 pm

Gilead Sciences

EXCLUSIVE: 340B Program Purchases Reach $24.3 Billion—7%+ of the Pharma Market—As Hospitals’ Charity Care Flatlines

Drug Channels

Tue, 05/14/19 - 09:55 am

‘Too big to care’: Sweeping lawsuit accuses Teva of colluding with other generic makers to keep prices high

Endpoints

Mon, 05/13/19 - 09:18 am

Teva Pharmaceutical

price collusion

White House, Congress considering killing Part D rebate rule, creating spending cap

BioCentury

Fri, 05/10/19 - 06:00 pm

Medicare Part D

Pages